Former President Joe Biden has been diagnosed with an aggressive form of prostate cancer, though his team has confirmed that the disease is hormone-sensitive, which offers a more favorable prognosis and effective treatment options. The condition, which has seen a 3% annual increase in cases since 2014, affects over 300,000 Americans annually. Biden’s office announced the diagnosis on Sunday, following the discovery of a “small nodule” during a routine examination. The president is now in discussions with his medical team to determine the most suitable treatment plan.
Prostate cancer, a cancer that develops in the prostate gland, is the second-most common cancer in men, behind skin cancer, with an estimated 313,780 new cases projected in 2025. While age remains the primary risk factor, the average age of diagnosis is 67, and men over 65 are disproportionately affected. Although rare in men under 40, the disease is still a serious health concern, particularly for those in later years of life. Biden, at 82, falls into the high-risk category and will need to carefully consider treatment options.
Ancillary to his condition, Biden’s diagnosis has sparked broader interest in the medical community, especially regarding early detection and advancements in treatment. Hormone-sensitive prostate cancer, which responds well to hormone therapy, has a more optimistic outlook compared to more aggressive and drug-resistant variants. These therapies typically block testosterone, which fuels the growth of cancer cells. In addition to hormone therapy, other treatment options include chemotherapy, targeted therapy, immunotherapy, and radiopharmaceuticals, which may be combined for more comprehensive care.
While early detection is vital, the U.S. Preventive Services Task Force advocates for men aged 55 to 69 to consider PSA-based screening to monitor for the disease. However, the Task Force acknowledges that screening comes with potential risks, such as false-positive results and overdiagnosis, which may lead to unnecessary treatments and complications. Researchers are working on alternative screening methods, including a non-invasive urine test designed to offer better and more precise results than the traditional PSA test.
Despite the challenges, the prognosis for localized or regional prostate cancer is quite positive, with a five-year survival rate of at least 99% for men diagnosed at these early stages. For those in advanced stages, where the cancer has spread to other areas of the body, survival rates are significantly lower. While Biden faces a difficult medical journey, the hormone-sensitive nature of his condition gives hope for effective and targeted treatment, as his team reviews the best possible options for his care.
.